Can-Fite BioPharma (CANF) Total Liabilities (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Total Liabilities came in at $9.5 million in Q4 2025, up 4.32% YoY from $9.1 million in Q4 2024, and up 23.24% on a QoQ basis from $7.7 million in Q2 2025.
Can-Fite BioPharma (CANF) Total Liabilities (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 13 years of Total Liabilities data on file, last reported at $9.5 million in Q4 2025.
- Quarterly Total Liabilities rose 4.32% year-over-year to $9.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.5 million (up 4.32% YoY) and the FY2025 annual result came in at $9.5 million, up 4.32% from the prior year.
- Total Liabilities rose to $9.5 million in Q4 2025, from $7.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $20.3 million in Q4 2021 to a low of $5.9 million in Q2 2024.
- A 5-year average of $11.7 million and a median of $10.5 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities jumped 112.67% — and 2022, when it slumped 54.16%.
- Tracing CANF's Total Liabilities over 5 years: stood at $20.3 million in 2021, then tumbled by 54.16% to $9.3 million in 2022, then climbed by 7.61% to $10.0 million in 2023, then slipped by 8.7% to $9.1 million in 2024, then advanced by 4.32% to $9.5 million in 2025.
- The last three Total Liabilities figures came in at $9.5 million (Q4 2025), $7.7 million (Q2 2025), and $9.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 10.03 Bn |
| 10 | Can-Fite BioPharma | 2.77 Mn | -8.78 Mn | - | 9.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.51 Mn |
| Jun 30, 2025 | 7.72 Mn |
| Dec 31, 2024 | 9.12 Mn |
| Jun 30, 2024 | 5.92 Mn |
| Dec 31, 2023 | 9.99 Mn |
| Sep 30, 2023 | 9.17 Mn |
| Jun 30, 2023 | 11.03 Mn |
| Mar 31, 2023 | 13.49 Mn |
| Dec 31, 2022 | 9.28 Mn |
| Sep 30, 2022 | 12.71 Mn |
| Jun 30, 2022 | 14.75 Mn |
| Mar 31, 2022 | 17.85 Mn |
| Dec 31, 2021 | 20.25 Mn |
| Sep 30, 2021 | 14.64 Mn |
| Jun 30, 2021 | 9.68 Mn |
| Mar 31, 2021 | 12.74 Mn |
| Dec 31, 2020 | 9.52 Mn |
| Sep 30, 2020 | 13.33 Mn |
| Jun 30, 2020 | 12.80 Mn |
| Dec 31, 2019 | 8.17 Mn |